trifectUserMessage

billToLabel

nonTrifectaUserMessage

requireAuthentication

unValidatedMessage

unregisteredMessage

requireRegistration

requiresValidation

unauthenticatedMessage

siteLink

siteLogo

headerLinks

Header Links

parentCompanyLink

mainSiteLink

footerLinks

Footer Links

copyrights

opcoLogos

Opco Logos

trademarks

parentCompanyLogo

mainSiteLinkText

regulatory

siteRobotsTXT

gtmId

footerGTMScript

headerGTMScript

Content Source Notes

MAPSS Code

Alert banners

Outage Alert

isExternal

description

title

style

checkCommerceEnabled

Copyright

Legal

Online Terms of Use

Patents

Privacy Statement

Sitemap

Danaher Life Sciences

Dashboard

Quotes

Scheduled Orders

Order History

order-center

redeemQuotePage

The CD85k antigen (ILT3) is a member of Immunoglobulin (Ig)-Like Transcripts (ILT), also known as Leucocyte Ig-like Receptors (LIR) and Monocyte / Macrophage Ig-like Receptors (MIR). ILT are expressed on monocytes, macrophages, dendritic cells (DCs) and granulocytes, except ILT2, which is expressed by both myeloid and lymphoid cells: NK, T cell subsets and all peripheral B cells. All ILT receptors except (ILT6) are transmembrane proteins and have been classified in 3 types: Inhibitory: ILT2, 3, 4, 5, LIR8; Activating: ILT1, LIR6a, 7, LIR8, with a cytoplasmic tail associated to FcRγ; Soluble: ILT6. The CD85k antigen (otherwise known as LIR-5, HM18) is a transmembrane protein of 60 kDa, constitutively phosphorylated. Unlike ILT2 and ILT4, ILT3 does not bind to HLA-A, -B and -G1 molecules. The ligand of ILT3 is unknown, however research studies point out the following functional properties: ILT3 is involved in antigen uptake and presentation; ILT3 negatively regulates Antigen Presenting Cell (APC) functional responses triggered via stimulatory receptors such as CD11b, CD16, MHC-class II. The transmission of a negative signal via ITIMs may be one of the inhibitory mechanisms, ranging from temporary to permanent inactivation, that control homeostasis, and immunological tolerance. It has been shown that ILT3, unregulated on monocytes and DCs by CD8+CD28- T suppressor cells, renders these APC tolerogenic.

The CD85k antigen (ILT3) is a member of Immunoglobulin (Ig)-Like Transcripts (ILT), also known as Leucocyte Ig-like Receptors (LIR) and Monocyte / Macrophage Ig-like Receptors (MIR).  ILT are expressed on monocytes, macrophages, dendritic cells (DCs) and granulocytes, except ILT2, which is expressed by both myeloid and lymphoid cells: NK, T cell subsets and all peripheral B cells. All ILT receptors except (ILT6) are transmembrane proteins and have been classified in 3 types: Inhibitory: ILT2, 3, 4, 5, LIR8; Activating: ILT1, LIR6a, 7, LIR8, with a cytoplasmic tail associated to FcRγ; Soluble: ILT6. The CD85k antigen (otherwise known as LIR-5, HM18) is a transmembrane protein of 60 kDa, constitutively phosphorylated. Unlike ILT2 and ILT4, ILT3 does not bind to HLA-A, -B and -G1 molecules. The ligand of ILT3 is unknown, however research studies point out the following functional properties: ILT3 is involved in antigen uptake and presentation; ILT3 negatively regulates Antigen Presenting Cell (APC) functional responses triggered via stimulatory receptors such as CD11b, CD16, MHC-class II. The transmission of a negative signal via ITIMs may be one of the inhibitory mechanisms, ranging from temporary to permanent inactivation, that control homeostasis, and immunological tolerance. It has been shown that ILT3, unregulated on monocytes and DCs by CD8+CD28- T suppressor cells, renders these APC tolerogenic.

The ZM3.8 antibody immunoprecipitates a protein of 55 kDa from ILT3-transfected T cells and a protein of 60 kDa from monocytes.

A46529, CD85k-PC7 Conjugated Antibody, ZM3.8, 1 mL, ASR

The CD85k antigen (ILT3) is a member of Immunoglobulin (Ig)-Like Transcripts (ILT), also known as Leucocyte Ig-like Receptors (LIR) and Monocyte / Macrophage Ig-like Receptors (MIR).

Learn more about this product on Beckman.com

CD85k-PC7, ZM3.8, 1 mL, ASR